Tag: <span>bictegravir</span>

Home / bictegravir
Post

New Integrase Inhibitor Matches Existing HIV Tx

SEATTLE — The investigational integrase inhibitor bictegravir worked as well as dolutegravir (Tivicay) and caused no serious side effects when used as part of a three-drug antiretroviral therapy regimen, a researcher said here. Bictegravir is now being evaluated in phase III studies. Viral suppression rates were high in both treatment arms and no one taking...

Post

Gilead HIV drug aces phase 2, teeing up tussle with GSK

Gilead is looking to bictegravir to defend its HIV franchise against GSK Gilead has posted upbeat phase 2 data on its next-generation integrase inhibitor bictegravir in HIV patients. The drug more than held its own against GlaxoSmithKline’s dolutegravir, setting the stage for a larger-scale comparison in phase 3 and potential scrap for a multibillion-dollar market. The trial...